Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models

Molecular Cancer Therapeutics

Volumn 12, Issue 7, 2013, Pages 1343-1355

  Tiwari, Amit K ^a   Zhang, Rong ^a   Gallo, James M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABCC4 TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG URINE LEVEL; IC 50; LIQUID CHROMATOGRAPHY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 84880081204     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0100     Document Type: Article

References (42)

1. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92. (Pubitemid 34800230)
2. Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: ef flux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004;21:25-51. (Pubitemid 38050202)
3. Kruh GD, Belinsky MG, Gallo JM, Lee K. Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. Cancer Metastasis Rev 2007;26:5-14. (Pubitemid 46452179)
4. Chen ZS, Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 2011;278:3226-45.
5. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 2002;99:15387-92. (Pubitemid 35403944)
6. Bruce JN, Fine RL, Canoll P, Yun J, Kennedy BC, Rosenfeld SS, et al. Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 2011;69:1272-9.
7. Wong ET, Berkenblit A. The role of topotecan in the treatment of brain metastases. Oncologist 2004;9:68-79. (Pubitemid 38134015)
8. Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol 2000;18:2459-67. (Pubitemid 30415833)
9. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1993;53:725-7. (Pubitemid 23077850)
10. Herben VM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996;31:85-102. (Pubitemid 26252687)
11. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989;32:715-20. (Pubitemid 19075732)
12. de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, van Tellingen O. Pglycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 2007;13:6440-9. (Pubitemid 350075034)
13. Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY, et al. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res 2005;22:1837-53. (Pubitemid 41504337)
14. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 2004;24:7612-21. (Pubitemid 39121487)
15. Shen J, Carcaboso AM, Hubbard KE, Tagen M, Wynn HG, Panetta JC, et al. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res 2009;69:5885-92.
16. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000;92:1651-6.
17. Verweij J, Lund B, Beijnen J, Planting A, de Boer-Dennert M, Koier I, et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993;4:673-8. (Pubitemid 23291814)
18. Robey RW, Lin B, Qiu J, Chan LL, Bates SE. Rapid detection of ABC transporter interaction: potential utility in pharmacology. J Pharmacol Toxicol Methods 2011;63:217-22.
19. Shukla S, Skoumbourdis AP, Walsh MJ, Hartz AM, Fung KL, Wu CP, et al. Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Mol Pharm 2011;8:1292-302.
20. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 2009;78:153-61.
21. Kawabe T, Chen ZS, Wada M, Uchiumi T, Ono M, Akiyama S, et al. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett 1999;456:327-31. (Pubitemid 29352317)
22. Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 2000;92:1934-40. (Pubitemid 32036924)
23. Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, Xiao ZJ, et al. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett 2013;328:307-17.
24. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42. (Pubitemid 17027905)
25. +/peptide cotransporter in rat digestive tract. Biochem Biophys Res Commun 1996;220:848-52.
26. Peng KC, Cluzeaud F, Bens M, Duong Van Huyen JP, Wioland MA, Lacave R, et al. Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney. J Histochem Cytochem 1999;47:757-68.
27. Belinsky MG, Guo P, Lee K, Zhou F, Kotova E, Grinberg A, et al. Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. Cancer Res 2007;67:262-8. (Pubitemid 46142783)
28. Wang Z, Zhou Q, Kruh GD, Gallo JM. Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos 2011;39:2155-61.
29. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine. Cancer Res 2003;63:6447-52. (Pubitemid 37255195)
30. Lagas JS, Vlaming ML, Schinkel AH. Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice. Mol Interv 2009;9:136-45.
31. Tiwari AK, Sodani K, Dai CL, Ashby CR Jr, Chen ZS. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 2011;12:570-94.
32. Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, et al. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993;53:1032-6. (Pubitemid 23087903)
33. Shah DK, Balthasar JP. Physiologically based pharmacokinetic model for topotecan in mice. J Pharmacokinet Pharmacodyn 2011;38:121-42.
34. Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, et al. Effect ofABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther 2005;4:650-8.
35. Takahashi N, Miura M, ScottSA, Kagaya H,Kameoka Y, TagawaH, et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 2010;55:731-7.
36. Sung C, Blaney SM, Cole DE, Balis FM, Dedrick RL. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 1994;54:5118-22. (Pubitemid 24313487)
37. Herben VM, Schoemaker nE, Rosing H, van Zomeren DM, ten Bokkel Huinink WW, Dubbelman R, et al. Urinary and fecal excretion of topotecan in patients with malignant solid tumours. Cancer Chemother Pharmacol 2002;50:59-64.
38. Rosing H, van Zomeren DM, Doyle E, Bult A, Beijnen JH. O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan. Anticancer Drugs 1998;9:587-92. (Pubitemid 28420054)
39. Matsumoto S, Yoshida K, Ishiguro N, Maeda T, Tamai I. Involvement of rat and human organic anion transporter 3 in the renal tubular secretion of topotecan [(S)-9-dimethylaminomethyl-10-hydroxy-camptothecin hydrochloride]. J Pharmacol Exp Ther 2007;322:1246-52.
40. Chen C, Slitt AL, Dieter MZ, Tanaka Y, Scheffer GL, Klaassen CD. Upregulation of Mrp4 expression in kidney of Mrp2-deficient TR- rats. Biochem Pharmacol 2005;70:1088-95. (Pubitemid 41262084)
41. Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, et al. Acomparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 1999;5:69-75. (Pubitemid 29045179)
42. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 2006;98:1739-42. (Pubitemid 44942712)